Rising Demand For Blood Transfusions Fuels Growth In The Sickle Cell Disease Treatment Market: A Key Driver Powering Sickle Cell Disease Treatment Market Growth In 2025

The Sickle Cell Disease Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Sickle Cell Disease Treatment Market Size and Its Estimated Growth Rate?
In the past few years, the market size for sickle cell disease treatment has witnessed a swift expansion. The sector, which is projected to be worth $2.95 billion in 2024, is expected to soar to $3.54 billion in 2025, marking a compound annual growth rate (CAGR) of 19.7%. Factors such as advanced comprehension of the disease, developments in blood transfusion methods, advances in pain management, and the growth of hydroxyurea therapy have contributed to this unprecedented growth during the historic period.

The market size for treatment of sickle cell disease is anticipated to experience a robust growth in the coming years. It's projected to reach a value of $6.8 billion in 2029, reflecting a compound annual growth rate (CAGR) of 17.7%. Factors contributing to this projected growth during the forecast period include gene editing and gene therapy, the development of new drugs, telemedicine and remote patient monitoring, and worldwide health initiatives. Some significant trends to watch out for during this period are curative treatments, alternative pain management strategies, global cooperative efforts, and increased patient advocacy and involvement.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13048

How Are Emerging Segments Shaping the Sickle Cell Disease Treatment Market Landscape?
The sickle cell disease treatment market covered in this report is segmented -

1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp

Which Growth Factors Are Influencing Sickle Cell Disease Treatment Market Expansion?
Anticipations about the growth of the sickle cell disease treatment market are being heightened by the growing dependency on blood transfusions. Serving as a medical process where blood or the components of the blood from one individual (the donor), are transferred to another (the recipient), blood transfusions are indispensable to the treatment plan for sickle cell disease (SCD) patients. This is due to their ability to enhance the blood's capacity to transport oxygen while mitigating the challenges that come with vaso-occlusion. A case in point, as on record in January 2022 by Mid-Atlantic Long-Term Care, a provider of specialized 24-hour triage on-call service based in the US, has it that daily, the United States needs around 29,000 units of red blood cells, 5,000 units of platelets and 6.500 units of plasma. As a result, this escalating need for blood transfusions bolsters the expansion of the sickle cell disease treatment market. Promoting expansion in the sickle cell disease treatment market is the upsurge in blood and bone marrow transplants. A blood and bone marrow transplant serves as a medical procedure that substitutes unhealthy blood-forming cells with healthier ones. The purpose of a bone marrow transplant is to heal sickle cell diseases and cancers through the infusion of healthy bone marrow cells into an individual post the treatment of their diseased bone marrow to eradicate the abnormal cells. The replacement cells are acquired either from the patient's own body, in autologous transplants, or from that of a donor, referred to as allogeneic transplants. Cited in June 2024 records of the National Transplant Organization (ONT), a Spain-based independent coordinating agency, Spain added 23,686 donors to the Spanish Bone Marrow Donor Registry in 2023, marking an 8% upturn from 2022. It also set a record with 3,717 hematopoietic stem cell transplants, which amounts to 77.4 transplants per million of the population. Therefore, this upswing in blood and bone marrow transplants proves advantageous for the sickle cell disease treatment market.

Who Are the Dominant Players Across Different Sickle Cell Disease Treatment Market Segments?
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

What Sickle Cell Disease Treatment Market Trends Are Gaining Traction Across Different Segments?
Key players in the sickle cell disease therapy market are channeling efforts towards the creation of new oral suspension drugs, to provide ease of administration, improve drug functionality, and generate more user-friendly treatment options, particularly for older individuals and children. Oral suspension drugs, essentially liquid medications with solid components mixed in, are tailored to simplify swallowing for patients, notably kids or people who have difficulty swallowing pills. For example, Akums Drugs and Pharmaceuticals Ltd., an Indian pharmaceuticals manufacturer, in March 2024, introduced an oral suspension of Hydroxyurea that can be stored at room temperature. This room-temperature-stable, cost-effective treatment for SCD aims to enhance reach in India. At a price less than 1% of foreign alternatives, it allows for accurate dosage through oral syringes suitable for patients across age groups, eliminating the need for refrigeration.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report

Which Geographic Regions Are Expected to Dominate the Sickle Cell Disease Treatment Market in the Coming Years?
North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Sickle Cell Disease Treatment Market?
2. What is the CAGR expected in the Sickle Cell Disease Treatment Market?
3. What Are the Key Innovations Transforming the Sickle Cell Disease Treatment Industry?
4. Which Region Is Leading the Sickle Cell Disease Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.